Innoviva
INVA

$19.36

1.58%

Market Cap: $1.21B

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

214% more call options, than puts

Call options by funds: $477K | Put options by funds: $152K

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

6% more capital invested

Capital invested by funds: $1.13B [Q1] → $1.2B (+$69.1M) [Q2]

5% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 77

0% more funds holding

Funds holding: 211 [Q1] → 211 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 26

0.05% less ownership

Funds ownership: 116.85% [Q1] → 116.8% (-0.05%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for INVA.

See Analyst Rankings

Financial journalist opinion

Innoviva to Participate in Upcoming Investor Conferences

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference Fo.

Innoviva to Participate in Upcoming Investor Conferences

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2024, and highlighted select corporate achievements. “Our robust second quarter continues to demon.

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024

Everything is expensive these days including stocks. Amid a raging bull market, it is tough to find affordable stocks to buy.

The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024

3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge

Finding high-growth stock opportunities is crucial to constructing a stable and prosperous portfolio. Three outstanding businesses set up for remarkable development in 2024 are highlighted here.

3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami,.

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

3 Under-$20 Stocks That Could Make You a Fortune

Purchasing stocks for less than $20 might be a wise choice for investors looking to make large gains without making big initial commitments. These three under-$20 stocks show promise.

3 Under-$20 Stocks That Could Make You a Fortune

Innoviva to Participate in the BofA Securities Health Care Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will present at the BofA Securities Health Care Conference in Las Vegas, NV on Wednesday, May 15, 2024 at 9:.

Innoviva to Participate in the BofA Securities Health Care Conference

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that positive results from the Phase 3 oral zoliflodacin trial will be highlighted in an oral presentation given by the Global Antibiotic Research & Development Partnership (GARDP) at the European Society of Clinical Microbiology and Infectious Disease Global Congress (ESCMID Global 2024) taking place April 27-30, 2024, in Barcelona, Spain. Zoliflodacin is a.

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the Company at closing are $35 million before deducting transaction-related expenses.

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

See News Rankings